Russian Federation vs Yemen: Average cost of multi drug-resistant tuberculosis treatment
Russian Federation
2,751 constant 2022 US$
in 2024
Yemen
2,510 constant 2022 US$
in 2024
Russian Federation rank
18th
Yemen rank
20th
Average cost of multi drug-resistant tuberculosis treatment over time
- Russian Federation
- Yemen
How they compare
Russian Federation currently reports 2,751 constant 2022 US$ against 2,510 constant 2022 US$ in Yemen, a difference of 241 constant 2022 US$.
That makes Russian Federation's figure about 1.1 times Yemen's.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was Russian Federation ahead.
Russian Federation ranks 18th and Yemen ranks 20th of 92 countries.
Yemen has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Russian Federation | Yemen | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,647 constant 2022 US$ | 2,720 constant 2022 US$ | 73 constant 2022 US$ | Yemen |
| 2020s | 2,770 constant 2022 US$ | 2,987 constant 2022 US$ | 216.33 constant 2022 US$ | Yemen |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Russian Federation or Yemen?
- Russian Federation, at 2,751 constant 2022 US$ against 2,510 constant 2022 US$ in Yemen as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Russian Federation and Yemen?
- 241 constant 2022 US$, with Russian Federation ahead.
- How many years of comparable data are there for Russian Federation and Yemen?
- 6 years are reported by both, from 2017 to 2024.
- How do Russian Federation and Yemen rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Russian Federation ranks 18th and Yemen ranks 20th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.